​

Myriad Genetics (MYGN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

MYGN Stock Forecast

Myriad Genetics (MYGN) stock forecast, based on 36 Wall Street analysts, predicts a 12-month average price target of $6.00, with a high of $6.00 and a low of $6.00. This represents a 23.71% increase from the last price of $4.85.

- $6 $12 $18 $24 $30 High: $6 Avg: $6 Low: $6 Last Closed Price: $4.85

MYGN Stock Rating

Myriad Genetics stock's rating consensus is Hold, based on 36 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (22.22%), 22 Hold (61.11%), 6 Sell (16.67%), and 0 Strong Sell (0.00%).

Hold
Total 36 0 6 22 8 Strong Sell Sell Hold Buy Strong Buy

MYGN Price Target Upside V Benchmarks

TypeNameUpside
StockMyriad Genetics23.71%
SectorHealthcare Stocks 15.45%
IndustryDiagnostics & Research Stocks34.89%

Price Target Trends

1M3M12M
# Anlaysts115
Avg Price Target$6.00$6.00$9.00
Last Closing Price$4.85$4.85$4.85
Upside/Downside23.71%23.71%85.57%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 262171112
Feb, 262171112
Jan, 262171112
Dec, 252171112
Nov, 252181113
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 24, 2026Lu LiUBS$6.00$4.7127.39%23.71%
Nov 04, 2025Lu LiUBS$8.00$8.18-2.20%64.95%
May 07, 2025Bill BonelloCraig-Hallum$18.00$7.27147.59%271.13%
May 07, 2025Lu LiUBS$7.00$7.27-3.71%44.33%
May 07, 2025Brandon CouillardWells Fargo$6.00$7.27-17.47%23.71%
Mar 12, 2025Piper Sandler$12.50$10.4120.08%157.73%
Mar 04, 2025Piper Sandler$11.50$10.4210.36%137.11%
Dec 09, 2024Puneet SoudaLeerink Partners$21.00$15.1538.61%332.99%
Oct 14, 2024Sung Ji NamScotiabank$34.00$24.6737.82%601.03%
Sep 19, 2024Tejas SavantMorgan Stanley$32.00$28.4712.40%559.79%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 24, 2026UBSNeutralNeutralhold
Nov 04, 2025Cowen & Co.HoldHoldhold
Nov 04, 2025UBSNeutralNeutralhold
May 21, 2025ScotiabankSector OutperformSector Performdowngrade
May 07, 2025Craig-HallumBuyBuyhold
May 07, 2025UBSNeutralNeutralhold
May 07, 2025Wells FargoOverweightCautiousdowngrade
Mar 12, 2025Piper SandlerNeutralOverweightupgrade
Dec 09, 2024Leerink PartnersOutperformMarket Performdowngrade
Oct 14, 2024ScotiabankSector OutperformSector Outperformhold

Financial Forecast

EPS Forecast

$-4 $-3 $-2 $-1 $0 $1 $2 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.35$-1.39$-3.18$-1.41$-3.96---
Avg Forecast$-0.73$-0.34$-0.30$0.13$0.15$0.37$0.62$0.73
High Forecast$-0.59$-0.33$-0.29$0.15$0.35$1.33$0.62$0.74
Low Forecast$-0.86$-0.36$-0.31$0.12$-0.24$-0.45$0.61$0.72
Surprise %-52.05%308.82%960.00%-1184.62%-2740.00%---

Revenue Forecast

$650M $730M $810M $890M $970M $1B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$690.60M$678.40M$753.20M$837.60M$824.50M---
Avg Forecast$691.23M$670.07M$751.44M$839.85M$876.33M$955.37M$998.09M$1.03B
High Forecast$698.75M$689.86M$752.10M$842.95M$885.04M$959.12M$1.00B$1.04B
Low Forecast$678.12M$655.62M$750.03M$836.98M$865.74M$951.62M$992.91M$1.01B
Surprise %-0.09%1.24%0.23%-0.27%-5.91%---

Net Income Forecast

$-400M $-290M $-180M $-70M $40M $150M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-27.20M$-112.00M$-263.30M$-127.30M$-365.90M---
Avg Forecast$-47.96M$-35.67M$-263.30M$11.05M$4.40M$-11.72M$50.94M$60.82M
High Forecast$-28.53M$-17.71M$-138.45M$12.28M$28.58M$109.79M$51.60M$61.60M
Low Forecast$-67.39M$-53.63M$-388.15M$9.82M$-19.78M$-37.56M$50.14M$59.86M
Surprise %-43.28%213.96%--1252.11%-8422.19%---

MYGN Forecast FAQ

Is Myriad Genetics stock a buy?

Myriad Genetics stock has a consensus rating of Hold, based on 36 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 22 Hold, 6 Sell, and 0 Strong Sell, reflecting a consensus that Myriad Genetics is a neutral investment for most analysts.

What is Myriad Genetics's price target?

Myriad Genetics's price target, set by 36 Wall Street analysts, averages $6 over the next 12 months. The price target range spans from $6 at the low end to $6 at the high end, suggesting a potential 23.71% change from the previous closing price of $4.85.

How does Myriad Genetics stock forecast compare to its benchmarks?

Myriad Genetics's stock forecast shows a 23.71% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the diagnostics & research stocks industry (34.89%).

What is the breakdown of analyst ratings for Myriad Genetics over the past three months?

  • March 2026: 16.67% Strong Buy, 8.33% Buy, 58.33% Hold, 8.33% Sell, 8.33% Strong Sell.
  • February 2026: 16.67% Strong Buy, 8.33% Buy, 58.33% Hold, 8.33% Sell, 8.33% Strong Sell.
  • January 2026: 16.67% Strong Buy, 8.33% Buy, 58.33% Hold, 8.33% Sell, 8.33% Strong Sell.

What is Myriad Genetics’s EPS forecast?

Myriad Genetics's average annual EPS forecast for its fiscal year ending in December 2026 is $0.37, marking a -109.34% decrease from the reported $-3.96 in 2025. Estimates for the following years are $0.62 in 2027, and $0.73 in 2028.

What is Myriad Genetics’s revenue forecast?

Myriad Genetics's average annual revenue forecast for its fiscal year ending in December 2026 is $955.37M, reflecting a 15.87% increase from the reported $824.5M in 2025. The forecast for 2027 is $998.09M, and $1.03B for 2028.

What is Myriad Genetics’s net income forecast?

Myriad Genetics's net income forecast for the fiscal year ending in December 2026 stands at $-11.72M, representing a -96.80% decrease from the reported $-366M in 2025. Projections indicate $50.94M in 2027, and $60.82M in 2028.